Indications up for PET
Wednesday, 16 July, 2008
The Australian Government has expanded approved indications for Medicare reimbursement for PET imaging.
The inclusion of ovarian cancer, colorectal cancer and recurrent melanoma brings to a total of six the number of PET indications which are approved for reimbursement through Medicare.
One company poised to take advantage of this decision is Cyclopharm [ASX: CYC], which has already commenced development of two PET radiopharmacy sites.
The first is to be built at the Macquarie University Private Hospital, and should be completed in the first half of next year.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
